Target validation in silico: Does the virtual patient cure the pharma pipeline?

Expert Opinion on Therapeutic Targets

Volumn 10, Issue 5, 2006, Pages 635-638

  Alkema, Wynand ^a   Rullmann, Ton ^a   van Elsas, Andrea ^a  

^a NV ORGANON   (Netherlands)

Author keywords

Biosimulation; In silico modelling; Target validation; Virtual patient

Indexed keywords

ANTIDIABETIC AGENT; NEW DRUG; PLACEBO;

CLINICAL TRIAL; COMPUTER MODEL; COMPUTER PROGRAM; COMPUTER SIMULATION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; EDITORIAL; GENOMICS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; OUTCOMES RESEARCH; PHENOTYPIC VARIATION; PREDICTION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE; VALIDATION STUDY; VIRTUAL REALITY;

COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PHENOTYPE; REPRODUCIBILITY OF RESULTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 33749244440     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.10.5.635     Document Type: Editorial

References (17)

1. HOPKINS AL, GROOM CR: The druggable genome. Nat. Rev. Drug Discov. (2002) 1(9):727-730.
2. AERTS S, LAMBRECHTS D, MAITY S et al.: Gene prioritization through genomic data fusion. Nat. Biotechnol. (2006) 24(5):537-544.
3. PEREZ-IRATXETA C, WJST M, BORK P, ANDRADE MA: G2D: a tool for mining genes associated with disease. BMC Genet. (2005) 6:45.
4. FREUDENBERG J, PROPPING P: A similarity-based method for genome-wide prediction of disease-relevant human genes. Bioinformatics (2002) 18(Suppl. 2):S110-S115.
5. SEARLS DB: Data integration: challenges for drug discovery. Nat. Rev. Drug Discov. (2005) 4(1):45-58.
6. FISCHER HP: Towards quantitative biology: integration of biological information to elucidate disease pathways and to guide drug discovery. Biotechnol. Ann. Rev. (2005) 11:1-68.
7. KOLA I, LANDIS J: Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. (2004) 3(8):711-715.
8. WILEY HS, SHVARTSMAN SY, LAUFFENBURGER DA: Computational modeling of the EGF-receptor system: a paradigm for systems biology. Trends Cell Biol. (2003) 13(1):43-50.
9. EUNGDAMRONG NJ, IYENGAR R: Computational approaches for modeling regulatory cellular networks. Trends Cell Biol. (2004) 14(12):661-669.
10. NOBLE D: Modeling the heart-from genes to cells to the whole organ. Science (2002) 295(5560):1678-1682.
11. PERELSON AS: Modelling viral and immune system dynamics. Nat. Rev. Immunol. (2002) 2(1):28-36.
12. MUSANTE CJ, LEWIS AK, HALL K: Small- and large-scale biosimulation applied to drug discovery and development. Drug Discov. Today (2002) 7(20 Suppl.):S192-S196.
13. WILLIS RC: The virtual patient. Mod. Drug Discov. (2003) 6(2):35-40.
14. MICHELSON S: Assessing the impact of predictive biosimulation on drug discovery and development. J. Bioinform. Comput. Biol. (2003) 1(1):169-177.
15. RULLMANN JAC, STRUEMPER H, DEFRANOUX NA, RAMANUJAN S, MEEUWISSE CML, VAN ELSAS A: Systems biology for battling rheumatoid arthritis. IEE Proc. Syst. Biol. (2005) 152(4):256-262.
16. VAN DER HELM-VAN MIL AH, VERPOORT KN, BREEDVELD FC, HUIZINGA TW, TOES RE, DE VRIES RR: The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum. (2006) 54(4):1117-1121.
17. KANSAL AR, TRIMMER J: Application of predictive biosimulation within pharmaceutical clinical development: examples of significance for translational medicine and clinical trial design. IEE Proc. Syst. Biol. (2005) 152(4):214-220.